Revvity, Inc. (RVTY) Tax Rate: 9.62%
Is Revvity, Inc.’s tax rate high or low?
Revvity, Inc.'s tax rate of 9.62% is 35% below its 5-year average of 14.85%, around the middle of its 5-year range (1.90%–26.10%).
4.18% below its 12-month average of 10.04%.
RVTY Tax Rate Chart
RVTY Average Tax Rate Chart
RVTY Current vs Average Tax Rate Chart
RVTY Tax Rate Metrics
TAX RATE
9.62%
TAX RATE AVG TTM
10.04%
TAX RATE AVG 3Y
10.83%
TAX RATE AVG 5Y
14.85%
TAX RATE AVG 10Y
15.38%
TAX RATE AVG 15Y
10.28%
TAX RATE AVG 20Y
11.72%
CURRENT VS TTM AVG
-4.18%
CURRENT VS 3Y AVG
-11.19%
CURRENT VS 5Y AVG
-35.22%
CURRENT VS 10Y AVG
-37.47%
CURRENT VS 15Y AVG
-6.43%
CURRENT VS 20Y AVG
-17.93%
Revvity, Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. Tax Rate FAQ
- What is the tax rate for Revvity, Inc. (RVTY)?
- The tax rate for RVTY stock is 9.62%.
- Is Revvity, Inc.'s tax rate high or low?
- Revvity, Inc.'s tax rate of 9.62% is 35% below its 5-year average of 14.85%, around the middle of its 5-year range (1.90%–26.10%).
- What is the TTM average tax rate for Revvity, Inc. (RVTY)?
- The TTM average tax rate for RVTY stock is 10.04%.
- What is the 3Y average tax rate for Revvity, Inc. (RVTY)?
- The 3Y average tax rate for RVTY stock is 10.83%.
- What is the 5Y average tax rate for Revvity, Inc. (RVTY)?
- The 5Y average tax rate for RVTY stock is 14.85%.
- What is the 10Y average tax rate for Revvity, Inc. (RVTY)?
- The 10Y average tax rate for RVTY stock is 15.38%.
- What is the 15Y average tax rate for Revvity, Inc. (RVTY)?
- The 15Y average tax rate for RVTY stock is 10.28%.
- What is the 20Y average tax rate for Revvity, Inc. (RVTY)?
- The 20Y average tax rate for RVTY stock is 11.72%.
Revvity, Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-28 | 9.62% |
| 2024-12-29 | 10.46% |
| 2023-12-31 | 1.90% |
| 2022-12-31 | 21.35% |
| 2021-12-31 | 26.10% |
| 2020-12-31 | 19.67% |
| 2019-12-31 | 3.96% |
| 2018-12-31 | 7.84% |
| 2017-12-31 | 47.12% |
| 2016-12-31 | 11.62% |
| 2015-12-31 | 9.59% |
| 2014-12-31 | 4.97% |
| 2013-12-31 | -9.52% |
| 2012-12-31 | -35.29% |
| 2011-12-31 | 98.18% |
| 2010-12-31 | 16.09% |
| 2009-12-31 | 29.96% |
| 2008-12-31 | 14.14% |
| 2007-12-31 | 11.54% |
| 2006-12-31 | 21.50% |
| 2005-12-31 | 0.19% |
| 2004-12-31 | 23.62% |
| 2003-12-31 | 31.99% |
| 2002-12-31 | 51.64% |
| 2001-12-31 | 101.82% |
| 2000-12-31 | 40.43% |
| 1999-12-31 | 36.75% |
| 1998-12-31 | 34.62% |
| 1997-12-31 | 43.33% |
| 1996-12-31 | 32.21% |
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh